IP Library Patent Application 19140666
Patent Application
App. No. 19/140,666

PRODRUGS OF DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/140,666
Abstract

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and X are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

Claims (69)

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen, deuterium, alkyl, or haloalkyl;

R 2 , R 3 , R 4 , and R 5 , independently are hydrogen, deuterium, alkyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, —OH, —OD; or

R 2 and R 3 or R 4 and R 5 together are carbonyl;

R 6 is hydrogen, deuterium, alkyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, —OH, or —OD;

R 7 , R 8 , R 9 , and R 10 are independently hydrogen, deuterium, alkyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, halogen, —OH, or —OD;

R 11 is hydrogen, deuterium, alkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, halogen, —OH, —OMe, or —CN;

R 12 is COR 13 , CONHR 13 , COOR 13 ,

wherein R 13 , R 14 , R 16 , R 17 , R 18 , R 19 , and R 20 independently are hydrogen, deuterium, alkyl, or heteroalkyl; and

wherein R 15 is hydrogen, deuterium, alkyl, heteroalkyl, or carbonyl;

each X is independently —CR 21 or N;

wherein R 21 is hydrogen, halogen, or alkyl.

2 . The compound of claim 1 , wherein

R 1 is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl;

R 2 , R 3 , R 4 , and R 5 , independently are C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 heterocyclyl;

R 6 is C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 heterocyclyl;

R 7 , R 8 , R 9 , and R 10 independently are C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 heterocyclyl;

R 11 is C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 heterocyclyl;

R 12 is COR 13 , CONHR 13 , COOR 13 ,

wherein R 13 , R 14 , R 16 , R 17 , R 18 , R 19 , and R 20 independently are C 1 -C 6 alkyl or C 1 -C 6 heteroalkyl; and

wherein R 15 is C 1 -C 6 alkyl, or C 1 -C 6 heteroalkyl; and

each X independently is —CR 21 or N;

wherein R 21 is C 1 -C 6 alkyl.

3 . The compound of any of claims 1-2 , wherein R 9 is halogen.

4 . The compound of claim 3 , wherein R 9 is Cl.

5 . The compound of any of claims 1-4 , wherein R 7 is C 1 -C 6 alkyl.

6 . The compound of claim 5 , wherein R 7 is methyl.

7 . The compound of any of claims 1-6 , wherein each X is —CH.

8 . The compound of any of claims 1-6 , wherein at least one X is N.

9 . The compound of any of claims 1-7 , wherein at least two X are N.

10 . The compound of any of claims 1-9 , wherein R 1 is C 1 -C 6 alkyl.

11 . The compound of claim 10 , wherein R 1 is methyl.

12 . The compound of any of claims 1-11 , wherein R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 10 , and R 11 are hydrogen.

13 . The compound of any of claims 1-12 , wherein R 11 is C 1 -C 6 haloalkyl.

14 . The compound of claim 13 , wherein R 1 is —CF 3 .

15 . The compound of any of claims 1-12 , wherein R 11 is halogen.

16 . The compound of claim 15 , wherein R 1 is Cl.

17 . The compound of claim 15 , wherein R 11 is Br.

18 . The compound of claim 15 , wherein R 11 is F.

19 . The compound of any of claims 1-18 , wherein R 12 is

20 . The compound of any of claims 1-18 , wherein R 12 is

21 . The compound of claim 20 , wherein R 19 is hydrogen.

22 . The compound of any of claims 20-21 , wherein R 20 is C 1 -C 6 alkyl.

23 . The compound of claim 22 , wherein R 20 is methyl.

24 . The compound of any of claims 1-18 , wherein R 12 is

25 . The compound of claim 24 , wherein R 17 is hydrogen.

26 . The compound of any of claims 24-25 , wherein R 18 is C 1 -C 6 alkyl.

27 . The compound of claim 26 , wherein R 18 is methyl.

28 . The compound of any of claims 1-18 , wherein R 12 is

29 . The compound of claim 28 , wherein R 14 is C 1 -C 6 alkyl.

30 . The compound of claim 29 , wherein R 14 is methyl.

31 . The compound of any of claims 28-30 , wherein R 15 is carbonyl.

32 . The compound of any of claims 28-31 , wherein R 16 is C 1 -C 6 alkyl.

33 . The compound of claim 32 , wherein R 16 is —C(CH 3 ) 3 .

34 . The compound of any of claims 1-18 , wherein R 12 is —COR 13 .

35 . The compound of claim 34 , wherein R 13 is C 1 -C 6 heteroalkyl.

36 . The compound of claim 35 , wherein R 13 is —CH 2 NH 2 .

37 . The compound of any of claims 1-18 , wherein R 12 is —COOR 13 .

38 . The compound of claim 37 , wherein R 13 is C 1 -C 6 alkyl.

39 . The compound of claim 38 , wherein R 13 is ethyl.

40 . A compound selected from:

41 . A composition comprising the compound of any of claims 1-40 and a pharmaceutically acceptable carrier.

42 . A method for treating one or more conditions that are responsive to serotonin receptor activation, comprising administering to a subject in need thereof an effective amount of the compound of any of claims 1-40 or the composition of claim 41 .

43 . A method of treating a neurological disorder, comprising administering to a subject in need thereof an effective amount of the compound of any of claims 1-40 or the composition of claim 41 .

44 . The method of claim 43 , wherein the neurological disorder is major depressive disorder (MDD), treatment resistant depression (TRD), substance use disorder (SUD), an anxiety disorder including acute stress disorder agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, or specific phobia; an eating disorder including anorexia nervosa or bulimia nervosa; or rumination.

45 . A method of activating a 5-HT receptor comprising administering to a patient the compound of claim 1 .

46 . The method of claim 45 , wherein said 5-HT receptor is a 5-HT2A, 5-HT2B, or 5-HT2C receptor.

47 . The method of claim 46 , wherein said compound is one of the compounds of claim 40 .